Sanofi-Aventis Sa (SNY) 39.41 $SNY
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
CNW Group - Sat Jun 11, 10:01AM CDT
Sanofi announced today the release of the new real world data assessing the use of Toujeo(®) (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA(1c) (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76(th) Scientific Sessions in New Orleans, LA, U.S.A.
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 60.01 (-0.09), SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Regeneron, Sanofi Report Positive Dupilumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:52AM CDT
Regeneron (REGN) and Sanofi reported that a phase III study on dupilumab in moderate-to-severe atopic dermatitis patients met the primary and secondary endpoints.
ANIP: 52.05 (-1.64), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 60.01 (-0.09), SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Regeneron Reports Interim Data on Cholesterol Lowering Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:00AM CDT
Regeneron (REGN) presented positive interim data from a phase II proof-of-concept study on evinacumab for homozygous familial hypercholestrolemia.
ANIP: 52.05 (-1.64), AMGN: 154.78 (-2.00), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), NVO: 55.36 (-1.51), SNY: 39.41 (-1.45)
What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical
PR Newswire - Tue May 31, 7:10AM CDT
The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, ActiveWallSt.com has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:
HRTX: 19.17 (-0.42), TXMD: 8.81 (-0.22), RMTI: 8.85 (-0.56), SNY: 39.41 (-1.45)
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), SGEN: 40.38 (-0.63), SNY: 39.41 (-1.45)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 60.01 (-0.09), NVO: 55.36 (-1.51), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45)
FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes
PR Newswire - Wed May 25, 5:50PM CDT
Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the New Drug Application (NDA) for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. The 15-member panel voted 12 to 2 (1 panelist did not vote due to travel) to approve the fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide.
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
Zacks Equity Research - Zacks Investment Research - Wed May 25, 2:50PM CDT
Novo Nordisk (NVO) announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes.
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), NVO: 55.36 (-1.51), SNY: 39.41 (-1.45)
Lilly's (LLY) R&D Update, Targets 20 New Launches by 2023
Arpita Dutt - Zacks Investment Research - Wed May 25, 8:23AM CDT
Lilly's (LLY) key areas of focus are diabetes, oncology, immunology, neurodegeneration and pain.
PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), LLY: 73.95 (-0.48), SNY: 39.41 (-1.45)
Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical and Emotional Burden of Multiple Sclerosis
BusinessWire - Wed May 25, 12:00AM CDT
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the launch of vs.MS, a global initiative focused on highlighting and addressing the sometimes debilitating symptoms that accompany MS, as well as their daily impact on people living with and affected by the disease.
SNY: 39.41 (-1.45)
Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Tue May 24, 4:15PM CDT
Exelixis, Inc. (EXEL) announced positive top-line data from the phase II trial, CABOSUN, on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma (RCC).
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), SNY: 39.41 (-1.45), EXEL: 7.38 (+0.01)
New Cholesterol Treatment Now Available for Canadians
CNW Group - Tue May 24, 10:02AM CDT
As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENTTM
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
Arpita Dutt - Zacks Investment Research - Tue May 24, 7:07AM CDT
Sanofi's (SNY) diabetes combination drug will be coming up for review by an FDA advisory panel this week.
NVO: 55.36 (-1.51), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45)
Novartis' Cardiovascular Drug Gets Positive Recommendation
Zacks Equity Research - Zacks Investment Research - Mon May 23, 2:47PM CDT
Novartis AG (NVS) announced that its cardiovascular drug, Entresto, was given a class I recommendation, as per the updated clinical practice guidelines in both the U.S. and Europe.
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), SNY: 39.41 (-1.45), NVS: 78.94 (-1.57)
Bristol-Myers Reports Two-Year Overall Survival Opdivo Data
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:23AM CDT
Bristol-Myers (BMY) reported overall survival phase III data from two pivotal studies evaluating Opdivo versus Taxotere in previously treated metastatic non-small cell lung cancer.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45)
Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting
CNW Group - Sat Jun 11, 10:01AM CDT
Sanofi announced today the release of the new real world data assessing the use of Toujeo(®) (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA(1c) (average blood sugar levels) and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin. The results of the study were presented on June 11 at the American Diabetes Association 76(th) Scientific Sessions in New Orleans, LA, U.S.A.
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
Globe Newswire - Wed Jun 08, 5:43AM CDT
Sanofi Files Investor Presentation Regarding Proposed Acquisition of Medivation
MDVN: 60.01 (-0.09), SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Regeneron, Sanofi Report Positive Dupilumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:52AM CDT
Regeneron (REGN) and Sanofi reported that a phase III study on dupilumab in moderate-to-severe atopic dermatitis patients met the primary and secondary endpoints.
ANIP: 52.05 (-1.64), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
Globe Newswire - Wed Jun 01, 1:15PM CDT
Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation's Board of Directors
MDVN: 60.01 (-0.09), SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Regeneron Reports Interim Data on Cholesterol Lowering Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:00AM CDT
Regeneron (REGN) presented positive interim data from a phase II proof-of-concept study on evinacumab for homozygous familial hypercholestrolemia.
ANIP: 52.05 (-1.64), AMGN: 154.78 (-2.00), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), NVO: 55.36 (-1.51), SNY: 39.41 (-1.45)
What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical
PR Newswire - Tue May 31, 7:10AM CDT
The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, ActiveWallSt.com has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:
HRTX: 19.17 (-0.42), TXMD: 8.81 (-0.22), RMTI: 8.85 (-0.56), SNY: 39.41 (-1.45)
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), SGEN: 40.38 (-0.63), SNY: 39.41 (-1.45)
Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
Zacks Equity Research - Zacks Investment Research - Thu May 26, 9:20AM CDT
Sanofi's (SNY) fixed-ratio combination of Lantus and Lyxumia won FDA panel backing for the treatment of type II diabetes.
MDVN: 60.01 (-0.09), NVO: 55.36 (-1.51), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45)
FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes
PR Newswire - Wed May 25, 5:50PM CDT
Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the New Drug Application (NDA) for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. The 15-member panel voted 12 to 2 (1 panelist did not vote due to travel) to approve the fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide.
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45)
Novo Nordisk IDegLira Recommended by FDA Advisory Committee
Zacks Equity Research - Zacks Investment Research - Wed May 25, 2:50PM CDT
Novo Nordisk (NVO) announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes.
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), NVO: 55.36 (-1.51), SNY: 39.41 (-1.45)
Lilly's (LLY) R&D Update, Targets 20 New Launches by 2023
Arpita Dutt - Zacks Investment Research - Wed May 25, 8:23AM CDT
Lilly's (LLY) key areas of focus are diabetes, oncology, immunology, neurodegeneration and pain.
PFE: 35.29 (-0.02), AZN: 27.97 (-0.99), LLY: 73.95 (-0.48), SNY: 39.41 (-1.45)
Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical and Emotional Burden of Multiple Sclerosis
BusinessWire - Wed May 25, 12:00AM CDT
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the launch of vs.MS, a global initiative focused on highlighting and addressing the sometimes debilitating symptoms that accompany MS, as well as their daily impact on people living with and affected by the disease.
SNY: 39.41 (-1.45)
Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Tue May 24, 4:15PM CDT
Exelixis, Inc. (EXEL) announced positive top-line data from the phase II trial, CABOSUN, on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma (RCC).
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), SNY: 39.41 (-1.45), EXEL: 7.38 (+0.01)
New Cholesterol Treatment Now Available for Canadians
CNW Group - Tue May 24, 10:02AM CDT
As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENTTM
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Sanofi Diabetes Drugs Briefing Documents Raise Concerns
Arpita Dutt - Zacks Investment Research - Tue May 24, 7:07AM CDT
Sanofi's (SNY) diabetes combination drug will be coming up for review by an FDA advisory panel this week.
NVO: 55.36 (-1.51), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45)
Novartis' Cardiovascular Drug Gets Positive Recommendation
Zacks Equity Research - Zacks Investment Research - Mon May 23, 2:47PM CDT
Novartis AG (NVS) announced that its cardiovascular drug, Entresto, was given a class I recommendation, as per the updated clinical practice guidelines in both the U.S. and Europe.
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), SNY: 39.41 (-1.45), NVS: 78.94 (-1.57)
Bristol-Myers Reports Two-Year Overall Survival Opdivo Data
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:23AM CDT
Bristol-Myers (BMY) reported overall survival phase III data from two pivotal studies evaluating Opdivo versus Taxotere in previously treated metastatic non-small cell lung cancer.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45)
